Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres

Department of Endocrinology and Metabolism, Odense University Hospital, DK-5000 Odense, Denmark. steen.bonnema@dadlnet.dk

In routine use for more than 50 years, radioiodine ((131)I) is generally considered safe and devoid of major side effects. Therefore, it is surprising that relatively many aspects of radioiodine therapy are controversial, as illustrated by recent international questionnaire studies. Our review aims at highlighting three of these areas - namely, the influence of (131)I on the course of Graves' ophthalmopathy, the possible radioprotective effects of antithyroid drugs, and the use of (131)I in large goitres. (131)I therapy carries a small (but definite) risk of causing progression of Graves' ophthalmopathy. Identification of risk factors (thyroid dysfunction, high level of thyroid-stimulating hormone (TSH) receptor antibodies, cigarette smoking) allows the identification of patients at risk and the institution of concomitant glucocorticoid treatment, thereby hindering progression of eye disease. On the basis, largely, of retrospective data, it appears that carbimazole (or methimazole), if stopped 3-5 days before treatment, does not influence the outcome of (131)I therapy. Simultaneous thyrostatic medication most probably reduces the efficacy of (131)I, as does restarting it within 7 days. Propylthiouracil seems to have a more prolonged radioprotective effect than carbimazole. Surgery is the treatment of first choice in patients with a large goitre. However, in the case of patient ineligibility or preference, (131)I therapy may be an option. The treatment has a favourable effect on tracheal compression and inspiratory capacity, but the reduction in thyroid volume is only 30-40%. Inpatient treatment, necessitated by the large doses, makes the treatment cumbersome. Controversy related to radioiodine therapy is mainly based on the lack of adequate prospective randomised studies comparing efficacy, side effects, cost and patient satisfaction.

This article has been cited by other articles:

				J. C. Sisson, M. J. Schipper, C. C. Nelson, J. E. Freitas, and B. R. Frueh Radioiodine Therapy and Graves' Ophthalmopathy J. Nucl. Med., June 1, 2008; 49(6): 923 - 930. [Abstract] [Full Text] [PDF]

				P. Laurberg Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur. J. Endocrinol., December 1, 2006; 155(6): 783 - 786. [Abstract] [Full Text] [PDF]

				E. N Pearce Diagnosis and management of thyrotoxicosis. BMJ, June 10, 2006; 332(7554): 1369 - 1373. [Full Text] [PDF]

				P. Perros, P. Kendall-Taylor, C. Neoh, S. Frewin, and J. Dickinson A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients with Minimally Active Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5321 - 5323. [Abstract] [Full Text] [PDF]

				S. J. Bonnema, F. N. Bennedbaek, A. Veje, J. Marving, and L. Hegedus Propylthiouracil before 131I Therapy of Hyperthyroid Diseases: Effect on Cure Rate Evaluated by a Randomized Clinical Trial J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4439 - 4444. [Abstract] [Full Text] [PDF]

				I. Rodriguez-Gomez, J. Sainz, R. Wangensteen, J. M. Moreno, J. Duarte, A. Osuna, and F. Vargas Increased Pressor Sensitivity to Chronic Nitric Oxide Deficiency in Hyperthyroid Rats Hypertension, August 1, 2003; 42(2): 220 - 225. [Abstract] [Full Text] [PDF]

				A. Wild, A. Ramaswamy, P. Langer, I. Celik, V. Fendrich, B. Chaloupka, B. Simon, and D. K. Bartsch Frequent Methylation-Associated Silencing of the Tissue Inhibitor of Metalloproteinase-3 Gene in Pancreatic Endocrine Tumors J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1367 - 1373. [Abstract] [Full Text] [PDF]